[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343250-105":59,"doc-detail-343250-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","uninvited-reply-letter-a-commentary-on-association-of-glucagon-like-peptide-1-receptor-agonists-with-risk-of-cancers-evidence-from-a-drug-target-mendelian-randomization-and-clinical-trials","Uninvited Reply Letter - A commentary on ‘Association of glucagon-like peptide-1 receptor agonists with risk of cancers evidence from a drug target Mendelian randomization and clinical trials’","","Letter responding to an International Journal of Surgery article by Sun et al. examining the causal link between glucagon-like peptide 1 receptor agonists (GLP1RA) and cancer risk using Mendelian randomization (MR) combined with prior clinical trial data. The authors praise the innovative work but argue that methodological choices may be questionable, propose adding summary data-based MR (SMR) rather than relying on IVW with cis eQTL, and suggest using coding variants and co-localization approaches to improve rigor and reduce false positives.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/uninvited-reply-letter-a-commentary-on-association-of-glucagon-like-peptide-1-receptor-agonists-with-risk-of-cancers-evidence-from-a-drug-target-mendelian-randomization-and-clinical-trials/343250/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/uninvited-reply-letter-a-commentary-on-association-of-glucagon-like-peptide-1-receptor-agonists-with-risk-of-cancers-evidence-from-a-drug-target-mendelian-randomization-and-clinical-trials/343250.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What study is this letter responding to?","Question",{"text":112,"@type":113},"It responds to an article by Sun et al. in the International Journal of Surgery that used Mendelian randomization combined with prior clinical trial data to study the association between GLP1RA and cancer risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What methodological concern is raised about the MR approach?",{"text":117,"@type":113},"The authors question the use of cis eQTL for the drug target gene (GLP1R) as a proxy for GLP1RA exposure and the exclusive use of inverse variance weighting (IVW), suggesting summary-data based MR (SMR) methods may be more appropriate.",{"name":119,"@type":110,"acceptedAnswer":120},"What improvements do the authors propose for stronger evidence?",{"text":121,"@type":113},"They propose using GLP1R coding variants as pharmacogenetic proxies, leveraging MAGIC Consortium glucose GWAS data, and applying Bayesian co-localization and multiple hypothesis testing to increase rigor and reduce false-positive results.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343250,1790790435,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24,"preview_page_count":14,"preview_urls":144},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","’Uninvited Reply Letter   \nA commentary on ‘Association of glucagon-like peptide-1 receptor agonists with risk of cancersevidence from a drug target Mendelian randomization and clinical trials’  \nGuolin Zhang, MDa , Zhen Wang, MDb , Hanlin Yu, MDc,*, Xiangzhe Liu, MDc,*  \nDear Editor,  \nWe read carefully with interest the article by Sun et al. [1] published in the International Journal of Surgery. They used Mendelian randomization (MR) combined with data from previous clinical trials for the association between glucagon-like peptide 1 receptor agonists (GLP1RA) and the risk of developing cancers. This study found a causal relationship between GLP1RA and multiple cancers and was associated with an increased risk of cancers (e.g. colon cancer) and a decreased risk of cancers (e.g. breast cancer) . This ﬁnding contributes to the understanding of the genetic association between GLP1RA and cancer risk, provides a valuable scientiﬁc basis for cancer prevention and treatment, and offers constructive guidance for the clinical application of GLP1RA. We sincerely admire this innovative research, but would like to share some different thoughts about this study.  \nWe believe that the choice of methodology for this study maybe questionable or needs to be supplemented. This study used the available cis eQTL for the drug target gene (GLP1R) as a proxy for GLP1RA exposure and used the inverse variance weighting (IVW) method for MR analysis. Typically, the use of cis eQTL as instrumental variables requires the use of summary data-based Mendelian randomization (SMR)[2] methods. For example, Ji et al. adopted the use ofSMR rather than IVW forMR analyses to explore the causal relationship between GLP-1 agonists and diabetic retinopathy in the context of using cis eQTL of GLP1R asan instrumental variable. Therefore, we believe that  \naDepartment of Cardiology, The Second Hospital of Dalian Medical University, bDepartment of General Surgery, The First Afﬁliated Hospital of Dalian Medical University, Dalian, Liaoning and cDepartment ofEncephalology, The First Afﬁliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China  \nGuolin Zhang and Zhen Wang have contributed equally to this work.  \nSponsorships or competing interests that maybe relevant to content are disclosed atthe end of this article.  \n*Corresponding author. Address: Department ofEncephalology, The First Afﬁliated Hospital of Henan University ofChinese Medicine, Zhengzhou 450046, Henan, People’s Republic of China. Tel.: +[861323 396 2199. E-mail: yuwenhanlin163@163.com](861323 396 2199. E-mail: yuwenhanlin163@163.com) (H. Yu), and Tel.: +861 363 381 1923. E-mail: [liuxiangzhe@163.com](liuxiangzhe@163.com) (X. Liu).  \nCopyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. International Journal of Surgery (2024) 110:6034–6035  \nReceived 11 May 2024; Accepted 19 May 2024  \nPublished online 29 May 2024  \n[http://dx.doi.org/10.1097/JS9.0000000000001725](http://dx.doi.org/10.1097/JS9.0000000000001725)  \nincorporating the SMR approach may be warranted. Speciﬁcally, there may be too many inappropriate instrumental variables incorporated when using cis eQTL as instrumental variables, in which case the IVW approach alone may lead to the emergence of false-positive results.  \nSecond, the MAGIC Consortium recently released the latest randomised glucose genome-wide association (GWAS) data derived from 476 326 individuals[3] . In their study, GLP1R coding variants (including newly identiﬁed low-frequency coding variants) associated with random glucose were identiﬁed. In addition, these variants were shown to be strongly associa","cbCaiudnl9i0Yv6N","https://ap.wps.com/l/cbCaiudnl9i0Yv6N","pdf",200696,"English","# Letter to the editor\n## Rationale and critique of MR methodology\n## Use of coding variants and improved analyses\n## Conclusion and acknowledgements\n## Declarations and funding","[{\"question\":\"What study is this letter responding to?\",\"answer\":\"It responds to an article by Sun et al. in the International Journal of Surgery that used Mendelian randomization combined with prior clinical trial data to study the association between GLP1RA and cancer risk.\"},{\"question\":\"What methodological concern is raised about the MR approach?\",\"answer\":\"The authors question the use of cis eQTL for the drug target gene (GLP1R) as a proxy for GLP1RA exposure and the exclusive use of inverse variance weighting (IVW), suggesting summary-data based MR (SMR) methods may be more appropriate.\"},{\"question\":\"What improvements do the authors propose for stronger evidence?\",\"answer\":\"They propose using GLP1R coding variants as pharmacogenetic proxies, leveraging MAGIC Consortium glucose GWAS data, and applying Bayesian co-localization and multiple hypothesis testing to increase rigor and reduce false-positive results.\"}]","Uninvited Reply Letter - A commentary on ‘Association of glucagon-like peptide-1 receptor agonists with risk of cancers evidence from a drug target Mendelian randomization and clinical trials’ | PDF",1790050423,[145,149],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bd6c17f3fdc55cd6829029f26c1364c.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1eb699cead58538bc5f939e9adf1efdf.webp",982,1309]